Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication:A review

来源 :World Journal of Gastroenterology | 被引量 : 0次 | 上传用户:bvf
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Helicobacter pylori(H.pylori)eradication is considered a necessary step in the management of peptic ulcer disease,chronic gastritis,gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma.Standard triple therapy eradication regimens are inconvenient and achieve unpredictable and often poor results.Eradication rates are decreasing over time with increase in antibiotic resistance.Fermented milk and several of its component whey proteins have emerged as candidates for complementary therapy.In this context the current review seeks to summarize the current evidence available on their role in H.pylori eradication.Pertinent narrative/systematic reviews,clinical trials and laboratory studies on individual components including fermented milk,yogurt,whey proteins,lactoferrin,α-lactalbumin(α-LA),glycomacropeptide and immunoglobulin were comprehensively searched and retrieved from Medline,Embase,Scopus,Cochrane Controlled Trials Register and abstracts/proceedings of conferences up to May 2013.A preponderance of the evidence available on fermented milk-based probiotic preparations and bovine lactoferrin suggests a beneficial effect in Helicobacter eradication.Evidence forα-LA and immunoglobulins is promising while that for glycomacropeptide is preliminary and requires substantiation.The magnitude of the potential benefit documented so far is small and the precise clinical settings are ill defined.This restricts the potential use of this group as a complementary therapy in a nutraceutical setting hinging on better patient acceptability/compliance.Further work is necessary to identify the optimal substrate,fermentation process,dose and the ideal clinical setting(prevention/treatment,first line therapy/recurrence,symptomatic/asymptomatic,gastritis/ulcer diseases etc.).The potential of this group in high antibiotic resistance or treatment failure settings presents interesting possibilities and deserves further exploration. Helicobacter pylori (H. pylori) eradication is considered a necessary step in the management of peptic ulcer disease, chronic gastritis, gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Standard triple therapy eradication regimens are inconvenient and achieve unpredictable and often poor results. Eradication rates are decreasing over time with increase in antibiotic resistance. False milk and several of its component whey proteins have emergent candidates for complementary therapy. In this context the current review seeks to summarize the current evidence available on their role in H. pylori eradication. Pertinent narrative / systematic reviews, clinical trials and laboratory studies on individual components including fermented milk, yogurt, whey proteins, lactoferrin, alpha-lactalbumin (alpha-LA), glycomacropeptide and immunoglobulin were duly searched and retrieved from Medline, Embase, Scopus, Cochrane Controlled Trials Register and abstracts / proceedings of conferences up to May 2013. A preponderance of the evidence available on fermented milk-based probiotic preparations and bovine lactoferrin suggests a beneficial effect in Helicobacter eradication. Evidence for alpha-LA and immunoglobulins is promising while that for glycomacropeptide is preliminary and not substantiated. The magnitude of the potential benefit documented so far is small and the precise clinical settings are ill defined.This restricts the potential use of this group as a complementary therapy in a nutraceutical setting hinging on better patient acceptability / compliance. Future work is necessary to identify the optimal substrate, fermentation process, dose and the ideal clinical setting (prevention / treatment, first line therapy / recurrence, symptomatic / asymptomatic, gastritis / ulcer diseases etc.). The potential of this group in high antibiotic resistance or treatment failure settings presents prospective possibilities and deserves further exploration.
其他文献
消费者对家居想象空间的打开,离不开互联网分享经济的助力。“近一年以来,我买的家居产品都是在好好住上看到的。”好好住创始人冯驌说,“最近我还被同事嘲笑落伍,买了一个感
五年恍如一瞬。中国电信江苏公司(以下简称“江苏电信”)按照党的十八大“大力推进生态文明建设”的重要布局,创新设计党建生态区,以信息化助建基层党组织建设新模式,实施的
目的:分析艾滋病的临床特点以及抗病毒治疗对预后的影响。方法:分析我院86例艾滋病住院患者的临床资料。结果:86例患者中,68例好转,3例失访,3例转诊,4例放弃治疗,8例死亡。结
1、10月19日,水利部副部长蔡其华在北京会见了德国萨克森州环境和农业部部长施密德一行,双方就进一步促进水利领域的交流与合作交换了意见。2.10月20日,水利部党组中心组以“
目的:观察复方益肝灵胶囊预防抗结核药物所致肝损伤的临床效果。方法:选取肺结核患者96例,随机分为对照组和观察组各48例。对照组患者给予常规抗结核药物并口服葡醛内酯片治
自20世纪80年代试管内受精技术出现以来,我们一直不断探索提高胚胎质量的方法。现行的常规体外受精-胚胎移植(IVF-ET)方案都推荐过夜精卵共孵育受精[1],通过观察共孵育16~20h
Nonalcoholic fatty liver disease(NAFLD)is one of the most frequent causes of health problems in Western(industrialized)countries.Moreover,the incidence of infan
目的:探讨正常形态精子百分率对体外受精-胚胎移植(IVF-ET)治疗结局及新生儿的影响。方法:采用WHO严格标准法将精液标本分为3组:中度畸形组:正常形态精子百分率5%~10%,轻度畸
胎球蛋白A是由肝细胞产生并分泌入血的一种脂肪细胞激活素。动物实验表明,其能束附于胰岛素受体,既而抑制胰岛素活性。临床试验亦表明,高胎球蛋白A水平往往与机体存在胰岛素
目的探求脑室腹腔分流术在腹腔镜辅助下微创放置分流管腹腔端对肥胖患者的安全性和可行性。方法回顾性分析了我院2007年至2008年42名肥胖脑积水病人采用腹腔镜辅助下腹腔端置